Welcome to our dedicated page for Aveo Pharma news (Ticker: AVEO), a resource for investors and traders seeking the latest updates and insights on Aveo Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aveo Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aveo Pharma's position in the market.
AVEO Oncology (Nasdaq: AVEO) announced results from the Phase 1b portion of the DEDUCTIVE clinical trial for tivozanib (FOTIVDA®), combined with AstraZeneca's IMFINZI®, in advanced hepatocellular carcinoma (HCC). In seven patients, the combination exhibited a 29% partial response rate and a 71% disease control rate, with no dose-limiting toxicities reported. The Phase 2 portion is expected to enroll 30 additional subjects later this year. AVEO continues to pursue regulatory approval for tivozanib in relapsed or refractory renal cell carcinoma (RCC).
AVEO Oncology (Nasdaq: AVEO) has made significant strides in 2021, focusing on the launch of tivozanib for treating relapsed or refractory renal cell carcinoma (RCC). CEO Michael Bailey announced progress in commercial preparations ahead of a potential FDA approval on March 31, 2021. The company aims to extend tivozanib's patent exclusivity to November 2028. Key milestones include advancing pipeline projects and clinical trials, such as the Phase 1 study of AV-380. The overall outlook for AVEO suggests a transformational year aimed at enhancing shareholder value.
AVEO Oncology (Nasdaq: AVEO) announced that CEO Michael Bailey will speak at two upcoming virtual investor conferences. The H.C. Wainwright Virtual BioConnect Conference runs from January 11 to January 14, while the B. Riley Virtual Oncology Investor Conference takes place on January 20 at 1:30 PM ET. A replay of the H.C. Wainwright presentation will be available on AVEO's website, and a live webcast of the B. Riley presentation can also be accessed there. AVEO is focused on developing therapies for cancer patients, including its lead candidate, tivozanib, for advanced renal cell carcinoma.
AVEO Oncology (Nasdaq: AVEO) announced that CEO Michael Bailey will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 5:20 p.m. ET. The presentation will be followed by a Q&A session with the management team. A live webcast of the event will be available on the company's website, with a replay archived for 30 days. AVEO is focused on developing oncology treatments, notably its lead candidate tivozanib, which is approved in the European Union for advanced renal cell carcinoma and is pending regulatory review in the U.S.
BOSTON--AVEO Oncology (Nasdaq: AVEO) announced that CEO Michael Bailey will present at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 11:20 a.m. ET. A live webcast of the presentation will be available through the investors section of AVEO's website, with a replay accessible for 30 days following the event.
AVEO focuses on developing oncology medicines, including its lead candidate, tivozanib, approved in the EU for advanced renal cell carcinoma. The company is also evaluating other treatments and is committed to diversity and innovation.
AVEO Oncology (Nasdaq: AVEO) has appointed David Crist as Vice President of Sales. Mr. Crist is tasked with developing AVEO’s sales team in anticipation of the potential U.S. launch of tivozanib, a treatment for relapsed or refractory renal cell carcinoma. His extensive experience in oncology sales, including successful product launches, is expected to enhance AVEO’s commercial strategy. Tivozanib is already approved in the EU and is undergoing further development for the U.S. market.